Dr Chad Tang speaks to ecancer about metastasis-directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumour DNA (ctDNA) as a personalised biomarker.

The treatment involves radiation to active disease sites, with a significant three-year overall survival rate of 87%.

The study highlights the prognostic value of circulating tumour DNA and shows that radiation therapy can be a cost-effective alternative to standard systemic therapies, with manageable toxicity rates.